本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）第八届董事会第二十次 会议于2024年9月6日上午以现场及通讯相结合的方式召开，会议通知以邮件 方式送达各位董事。本次会议应出席董事9人，实际出席董事9人，实际参加表 决董事9人。本次会议的召集召开程序符合《公司法》和《公司章程》的有关 规定。会议由董事长王旭先生主持，与会董事以记名投票方式审议通过了《关 于不向下修正北陆转债转股价格的议案》。 根据《深圳证券交易所创业板股票上市规则》等相关规定和《北京北陆药 业股份有限公司向不特定对象发行可转换公司债券募集说明书》的有关约定， 自2024年8月19日至2024年9月6日，公司股票已出现在任意连续三十个交易日 中至少有十五个交易日的收盘价格低于当期转股价格（8.68元/股）的85%（即 7.38元/股）的情形，触发"北陆转债"转股价格的向下修正条款。鉴于公司当 前股价未能准确反映公司长期发展的内在价值，公司董事会综合考虑了公司基 本情况、市场环境以及全体股东和债券投资者的多方利益，同时基于对公司未 来发展的坚定信心，公 ...

1、自2024年8月19日至2024年9月6日，北京北陆药业股份有限公司（以下 简称"公司"）股票已出现在任意连续三十个交易日中至少有十五个交易日的 收盘价格低于当期转股价格（8.68元/股）的85%（即7.38元/股）的情形，触发 "北陆转债"转股价格的向下修正条款。 债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2024-056 北京北陆药业股份有限公司 关于不向下修正北陆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 2、公司于 2024 年 9 月 6 日召开第八届董事会第二十次会议审议通过了《关 于不向下修正北陆转债转股价格的议案》，公司董事会决定本次不向下修正"北 陆转债"转股价格，且自董事会审议通过后的次日起未来两个月内（即 2024 年 9 月 7 日至 2024 年 11 月 6 日），"北陆转债"如再次触发转股价格向下修 正条款，亦不提出向下修正方案。以 2024 年 11 月 7 日为首个交易日重新计算， 若再次触发"北陆转债"转股价格向下修正条款，届时董 ...

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 9 月 5 日投资者关系活动记录表 编号：【2024】第 023 号 | --- | --- | --- | |------------------|-------------------------------------|----------------------------------------------------------| | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | □业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称 | 工银瑞信：段玮、李敏、陈力睿 | | | 及人员姓名 | 交银施罗德：庄旨歆 | | | 时 间 | 2024 年 9 月 5 日 | | | | | | | 地 点 上市公司接 | 电话会议 证券事务代表：孙志芳 | | | 待人员姓名 | Q1 、公司的业务布局情况 | | | | 践行"化药+中药"双轮驱动的业务模式。 | | | | | | | | | ...

股票代码：300016 股票简称：北陆药业 公告编号：2024-055 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于控股子公司海昌药业碘克沙醇化学原料药获批上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册。 生产企业名称：浙江海昌药业股份有限公司 近日，北京北陆药业股份有限公司控股子公司浙江海昌药业股份有限公司 （以下简称"海昌药业"）收到国家药品监督管理局核准签发的碘克沙醇《化 学原料药上市申请批准通知书》。现将相关情况公告如下： 一、药品的基本情况 化学原料药通用名称：碘克沙醇 英文名/拉丁名：Iodixanol 化学原料药注册标准编号：YBY70912024 有效期：18 个月 包装规格：25.00kg/桶、20.00kg/桶 生产企业地址：浙江省玉环市沙门镇滨港工业城长顺路 36 号 1 登记号：Y20230000093 受理号：CYHS2360234 通知书编号：2024Y ...

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年半年度业绩说明会投资者关系活动记录表 编号：【2024】第 022 号 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|--------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | √业绩说明会 | | 活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称 及人员姓名 | 线上参与公司北陆药业 | 2024 年半年度网上业绩说明会的投资者 | | 时 间 | 2024 年 9 月 4 日下午 | 15:00-17:00 | | 地 点 | "约调研"小程序 | | | 上市公司接 | 董事长、总经理：王旭先生 独立董事：曹纲先生 | | ...

1 证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2024 年 8 月 30 日投资者关系活动记录表 编号：【2024】第 021 号 | --- | --- | --- | |-----------------------|-----------------------------------------------------|-----------------------------------------------------| | 投资者关系 \n活动类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | | 华安证券：谭国超 | 华安证券：刘洪飞 | | | 东方证券：陆佳晶 | 深圳红筹投资：闫静雅 | | 参与单位名称 | 博时基金：曹芮 | 睿眼投资：卢政扬 | | 及人员姓名 | 瑞业资产：丁小兆 | 金信基金：谭佳俊 | | | 万和证券：许俊武 | 长盛基金：杨秋鹏 | | | 富荣基金：杨皓童 | | | 时 间 | 2024 年 8 月 30 ...

股票代码：300016 股票简称：北陆药业 公告编号：2024-054 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于北陆转债预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300016 证券简称：北陆药业 2、债券代码：123082 债券简称：北陆转债 3、转股价格：人民币 8.68 元/股 4、转股时间：2021 年 6 月 11 日至 2026 年 12 月 6 日 5、根据《北京北陆药业股份有限公司向不特定对象发行可转换公司债券 募集说明书》（以下简称"《募集说明书》"）的规定：在本可转债存续期间，当 公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格低于当 期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交公 司股东大会表决。 自 2024 年 8 月 19 日至 2024 年 8 月 30 日，公司股票已有十个交易日的 收盘价低于当期转股价格（8.68 元/股）的 85%（即 7.38 元/股），预计后续将 可能触发"北陆转债 ...

1 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 市公司的关 | 上市公司核算 | 年期初占 2024 | 2024 年半年度占 用累计发生金额 | 2024 年半年 度占用资金的 | 2024 年半年 度偿还累计 | 2024 30 | 年 6 月 日占用资 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 的会计科目 | 用资金余额 | | | | | | 原因 | | | | | 联关系 | | | （不含利息） | 利息（如有） | 发生金额 | 金余额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | | - | - | | 前控股股东、实际控制人 | | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | ...

债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于召开2024年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）已于2024年8月28日在 巨潮资讯网（www.cninfo.com.cn）披露《2024年半年度报告》。 为便于广大投资者进一步了解公司2024年半年度经营情况，公司定于2024 年9月4日（星期三）下午15:00至17:00时在"约调研"小程序举行2024年半年 度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者 可登陆"约调研"小程序参与互动交流。为广泛听取投资者的意见和建议，提 前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信小程序中搜索"约调研"后，点击"网上说明会"， 搜索"北陆药业"参与交流； 股票代码：300016 股票简称：北陆药业 公告编号：2024-053 1 投资者依据提示，授权登入"约调研"小程序，即可参与交流。 出席本次半年度网上业绩说明会的人员有：公司董事长、总经理王旭先生； 独立董事曹 ...

Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥473.93 million, representing an increase of 8.20% compared to the same period last year[12]. - The net profit attributable to shareholders of the listed company reached approximately ¥19.54 million, a significant increase of 103.52% year-on-year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥19.11 million, showing a remarkable increase of 2045.64% compared to the previous year[12]. - The net cash flow from operating activities was approximately ¥122.56 million, reflecting a growth of 120.02% year-on-year[12]. - The total assets of the company at the end of the reporting period amounted to approximately ¥3.07 billion, an increase of 8.81% from the end of the previous year[12]. - The net assets attributable to shareholders of the listed company were approximately ¥1.67 billion, which is a slight increase of 1.31% compared to the end of the previous year[12]. - The basic earnings per share for the reporting period was ¥0.04, doubling from ¥0.02 in the same period last year[12]. - The diluted earnings per share increased to ¥0.07, up 40.00% from ¥0.05 in the previous year[12]. - The weighted average return on net assets was 1.18%, an increase of 0.64% compared to the previous year[12]. Product Sales and Market Expansion - The company's contrast agent products achieved sales revenue of CNY 279.81 million, representing a year-on-year growth of 10.85%[19]. - The sales revenue for the diabetes medication products reached CNY 66.73 million, with a significant year-on-year increase of 58.44%[20]. - The sales revenue of Jiuwei Zhenxin Granules was 68.58 million yuan, a year-on-year decrease of 17.24%[24]. - The company achieved significant revenue growth in overseas markets, with all contrast agent products successfully launched internationally[25]. - The company plans to enhance the market presence of Jiuwei Zhenxin Granules in Southeast Asia, with registration processes in Hong Kong and Thailand progressing as scheduled[23]. - The company is actively developing a series of health products around Jiuwei Zhenxin Granules to strengthen its brand influence in the anti-anxiety market[23]. - The company has established strategic partnerships with online healthcare platforms to expand the sales channels for Jiuwei Zhenxin Granules[22]. Acquisitions and Integrations - The acquisition of an 80% stake in Tianyuan Pharmaceutical has expanded the company's traditional Chinese medicine portfolio, adding 58 product approvals to its offerings[21]. - The company has successfully integrated Tianyuan Pharmaceutical into its consolidated financial statements starting from June 2024, enhancing its strategic layout in traditional Chinese medicine[16]. - The company completed the acquisition of 80% of Tianyuan Pharmaceutical for ¥202,000,000.00, holding an 80% stake, with the investment resulting in a loss of ¥1,127,281.25 during the reporting period[46]. - The company completed the acquisition of Tianyuan Pharmaceutical in June 2024, which has 58 traditional Chinese medicine approvals and generated nearly CNY 100 million in sales revenue for its core product in 2023[53]. Research and Development - The company’s R&D investment for the first half of 2024 was 35.45 million yuan, a decrease of 33.98% compared to the same period last year[27]. - The company has 34 projects in total under review or in development, an increase of 8 projects compared to the same period last year[26]. - The company has received approval for several new drug specifications, including Gadobutrol injection and Paroxetine enteric-coated sustained-release tablets[27]. - The company is focusing on a dual business model of chemical and traditional Chinese medicine to drive growth and expand its product line[29]. Financial Management and Investments - The company’s investment activities resulted in a net cash outflow of 461.02 million yuan, primarily due to the acquisition and purchase of financial products[42]. - The company reported a total of ¥839,000,000.00 in new financial assets purchased during the period, with ¥562,000,000.00 sold[47]. - The total amount of raised funds was ¥48,922.45 million, with ¥709.32 million invested during the reporting period, and a cumulative investment of ¥32,523.95 million[48]. - The company has a remaining unused amount of CNY 50.9115 million, which includes CNY 50.5668 million in raised funds[49]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[65]. - The company has received multiple environmental approvals for various projects, including a significant approval for a new R&D center in 2009[66]. - The company has undertaken various environmental impact reports for new production lines, including a project approved in January 2023 for iodine contrast agents[69]. - The company has implemented a self-monitoring plan for environmental pollutants, which is executed by a third-party testing company[75]. Corporate Governance and Shareholder Information - The company held its first extraordinary general meeting of 2024 on January 30, with a participation ratio of 19.22%[63]. - The annual general meeting for 2023 took place on May 13, with a participation ratio of 19.39%[63]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[63]. - The total number of common shareholders at the end of the reporting period is 28,527[90]. Risk Management - The company is actively monitoring industry policy changes and adjusting its operational strategies accordingly to mitigate risks from regulatory shifts[54]. - The company has established a robust risk management and control system for its R&D projects to ensure timely adjustments based on market conditions[58]. - The company emphasizes safety and environmental protection, having established comprehensive systems for managing safety and environmental risks in its production processes[59].